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Abstract 
 
Fca/m receptor (Fca/mR), a novel Fc receptor for IgA and IgM, is a type I 
transmembrane protein with an immunoglobulin (Ig)-like domain in the extracellular 
portion.  Although IgA and IgM bind to Fca/mR, the molecular and structural 
characteristics of the ligand-receptor interactions have been undetermined.  Here, we 
developed twelve monoclonal antibodies (mAbs) against mouse Fca/mR by immunizing 
mice deficient in Fca/mR gene.  Eight mAbs totally or partially blocked IgA and IgM 
bindings to Fca/mR.  These blocking mAbs bound to a peptide derived from the Ig-like 
domain of mouse Fca/mR, which is conserved not only in human and rat Fca/mR but 
also in polymeric Ig receptor (poly-IgR), another Fc receptor for IgA and IgM.  These 
results suggest that IgA and IgM bind to an epitope in the conserved amino acids in the 
Ig-like domain of Fca/mR as well as poly-IgR.  
 
Keywords; Fca/mR, Fc receptor, IgM, IgA, polymeric Immunoglobulin receptor, 
Immunoglobulin-like domain 
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Introduction 
 
   The receptors for Fc portions of immunoglobulins (FcR) mediates various 
immune responses upon binding to antibodies or immune complexes [1, 2].  Mice 
deficient in FcR genes for IgG (FcgRI, FcgRII, FcgRIII) and IgE (FceRI, FceRII) have 
revealed their physiological roles in immune responses in vitro and in vivo [3, 4].  
Although functional Fc receptors for IgM had been reported on subpopulations of 
human and rodent T, B and NK cells [5] [6] [7] [8] [9] [10], a gene encoding an Fcμ 
receptor had not previously been identified.  We finally cloned a novel Fc receptor for 
IgM, which was found to be also an Fc receptor for IgA, designated Fca/m receptor 
(Fca/mR) [11, 12].  The Fca/mR is a type I transmembrane protein with an 
immunoglobulin (Ig)-like domain in the extracellular portion, and is expressed on B 
cells and macrophages [11, 12].  The Fca/mR is an only IgM receptor identified on 
human and murine hematopoietic cells to date, and is thought to play a central role for 
immune responses mediated by IgM and IgA [13].   
   The Fca/mR genes were mapped to syntenic regions of mouse chromosome 
  Cho, et al 
 4 
1 (1F) and human chromosome 1 (1q32.3), near several other Fc receptors, including 
Fcγ receptors I, II, and III, Fcε receptor, and the polymeric Ig receptor (poly-IgR) [11].  
The  poly-IgR gene, another Fc receptor for IgM and IgA expressed on mucosal 
epithelial cells [14], is only 12 kbp apart from the Fca/mR in the Fc receptor gene 
cluster on chromosome 1 [15], suggesting that these two receptors seem to be closely 
related in their phylogenies.  The polyIgR contains five Ig-like domains in the 
extracellular portion.  We found a motif in the immunoglobulin (Ig)-like domain of 
human and mouse Fca/mR that is conserved in the first Ig-like domain of human, 
mouse and rat poly-IgR [11].  Although this region is important for IgM and IgA 
binding to the poly-IgR [14], the molecular and structural characteristics of IgA and 
IgM binding to Fca/mR has been unclear.   
   We have recently established twelve monoclonal antibodies (mAbs) against 
mouse Fca/mR (mFca/mR), some of which efficiently block the IgM and IgA bindings 
to Fca/mR.  By using these mAbs, we analyzed the molecular characteristics of the 
ligand binding by Fca/mR. 
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Materials and Methods 
 
Cells, mice, antibodies and peptides 
Ba/F3 and BW5147 is mouse pro-B and thymoma cell lines, respectively.  The Ba/F3 
and BW5147 transfectants stably expressing mFca/mR were established, as described 
[11].  Mice deficient in Fca/mR gene were established by using gene targeting strategy 
of ES cells (manuscript for preparation).  Fluorescein isothiocyanate 
(FITC)-conjugated streptavidin, mouse IgM and IgA were purchased from PharMingen 
(San Diego, CA).  The peptides generated based on a motif in the Ig-like domain of 
mFca/mR (VTIHCHYAPSSVNRHQRKYW)[11] and on chicken egg ovalbumin (OVA) 
(ISQAVHAAHAEINEAGR) were purchased from Peptide Institute, Inc. (Osaka, Japan) 
 
Establishment of monoclonal antibodies against mFca/mR 
1 x 107 Ba/F3 transfectant expressing mFca/mR emulsified with complete 
Freund adjuvant (Sigma, St. Louis, MO) were injcetd into both foot pads of an 
Fca/mR-deficient mouse on day 0 and 7.  On day 10, draining lymph node cells were 
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harvested and fused with Sp2/0 myeloma cells.  Hybridomas were grown on methyl 
cellurose plate (ClonaCell-HYR, Stem Cell Technologies, Seattle, WA), according to the 
manufacture’s instruction. 
 
Competitive binding analyses 
1 x 106 BW5147 transfectants expressing mFca/mR were incubated with a 
variable dose of each anti-mFca/mR mAb generated for 30 min at 40C.  To compare 
recognition sites by each anti-mFca/mR mAb generated one another, the transfectant 
were then washed with PBS and incubated with 0.05 ug/ml of a biotin-conjugated 
anti-mFca/mR mAb, followed with FITC-conjugated streptavidin.  To examine 
blocking ability for IgM and IgA bindings to the mFca/mR, 1 x 106 BW5147 
transfectants expressing mFca/mR were incubated with 0.5 ug/ml of each purified 
anti-mFca/mR mAb for 30 min at 40C, washed with PBS twice and then stained with 
FITC-conjugated mouse IgM or IgA.  To examine binding ability of anti-Fca/mR 
mAbs to the motif peptide conserved in Fca/mR and poly-IgR, 0.05 ug of each 
biotin-conjugated anti-mFca/mR mAb was incubated with a variable dose of the motif 
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peptide for 1 hour at 40C.  Then 1 x 106 BW5147 transfectants expressing mFca/mR 
were added into the mAbs-peptide mixture and incubated for 30 min at 40C, followed 
by FITC-conjugated streptavidin.  The transfectant was analyzed by FACS CaliburR 
(BD, San Diego, CA).   
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Results and Discussion 
 
Establishment of mAbs against the mFca/mR 
Although we had been trying to generate mAbs against mFca/mR by 
immunizing rats with the Ba/F3 transfectant expressing mFca/mR several times, we 
could generate only one anti-mFca/mR mAb (TX6) [11].  Furthermore, we could never 
generated anti-human Fca/mR (hFca/mR) mAb by immunizing mice with the hFca/mR 
antigens.  Because amino acid sequences of extracellular domain of Fca/mR are highly 
conserved among human, mouse and rat (80.2% identity between mouse and rat and 
51.3% between mouse and human) [11], we considered that the immunological 
tolerance against Fca/mR antigens may be a cause of difficulty for establishing 
anti-human and mouse Fca/mR mAbs.  In order to avoid immunological tolerance 
against mFca/mR antigens, we immunized a mouse deficient in Fca/mR gene, instead of 
rat or other species of animals, for generation of anti-mFca/mR with the 
mFca/mR-expressing Ba/F3 transfectant and successfully generated twelve 
anti-mFca/mR mAbs, designated TX57 to TX68 (Table 1). 
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Characterization of recognition sites by the anti-mFca/mR mAbs  
To characterize recognition sites by the anti-Fca/mR mAbs, we performed 
competitive binding analysis, by using the BW5147 transfectant expressing mFca/mR. 
The BW5147 transfectant was incubated with either mAb out of 12 mAbs generated and 
then stained with either biotinylated mAb, followed with FITC-conjugated streptavidin.  
Analyses by flow cytometry demonstrated that any of mAbs, except TX57, did not 
interfere in the binding of TX57 to the transfectant (Fig 1A).  Similarly, TX64 binding 
to the transfectant was not inhibited by any of mAbs other than TX64 itself (Fig 1B). 
These results suggest that TX57 and TX64 mAbs recognize epitopes different from 
those recognized by the other mAbs.  In contrast, TX58, TX59, TX60, TX61 and TX66 
mAbs and TX67 and TX68 mAbs, but not the other mAbs, completely or partially 
inhibited the binding of these mAbs one another to the transfectant, respectively (Fig 
1C, D and Table 2).  Similarly, TX62, TX63 and TX65 mAbs, but not the other mAbs, 
interfered in the binding of these mAbs one another to the transfectant (Fig 1E and 
Table 2).  It was of interest that TX58, TX59, TX60, TX61 and TX66 mAbs, but not 
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the others, cross-reacted with hFca/mR (Table 1 and data not shown), suggesting that 
these mAbs recognize an epitope conserved also in human Fca/mR.  Based on these 
results, we divided the mAbs into five groups that differed from each other in their 
recognition sites (Table 1).   
 
Blocking of ligand binding to the Fca/mR by the anti-Fca/mR mAbs 
Next, we examined whether IgM and IgA bindings to the mFca/mR could be 
blocked by the anti-mFca/mR mAbs.  The BW5147 transfectant expressing the 
mFca/mR was incubated with either anti-mFca/mR mAb and then further incubated 
with FITC-conjugated IgM or IgA.  As demonstrated in Fig 2 and Table 1, analyses 
by flow cytometry demonstrated that TX57 mAb in the group I totally inhibited the 
binding of both IgM and IgA to the transfectant.  All the mAbs in the groups III and IV 
(TX58, 59, 60, 61, 66, 67 and 68) partially inhibited the ligand binding.  In contrast, 
the mAbs in the groups II and V did not affect IgM and IgA bindings to the transfectant.  
These results suggested that the epitopes in the Fca/mR recognized by the mAbs in the 
groups I, III and IV are either the IgA and IgM binding site of the Fca/mR or physically 
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related to the ligand binding site. 
 
Binding to a peptide conserved in both Fca/mR and poly-IgR by the anti-mFca/mR 
mAbs 
   We previously found a motif in the Ig-like domain of human and mouse 
Fca/mR that is conserved in the first Ig-like domain of human, mouse and rat poly-IgR 
(Fig 3A[11]).  Previous reports suggested that this motif is important for IgM and IgA 
bindings to the poly-IgR [16, 17].  Thus, this region is predicted to be also important 
for IgA and IgM bindings to the Fca/mR.  To evaluate this possibility, we synthesized 
the peptides corresponding to this motif sequence (motif peptide) (Fig 3A) and to the 
chicken egg ovalbumin (OVA) as a control for competitive binding analyses.  Each 
anti-mFca/mR mAb was preincubated with the motif or control peptides and then used 
for staining of the BW5147 transfectant expressing the Fca/mR.  As demonstrated in 
Fig 3B and Table 1, pre-incubation of the mAbs in the groups I, III and IV with the 
motif peptide significantly decreased the antibody binding to the transfectant.  In 
contrast, the binding of any of the mAbs in the groups II and V to the transfectant were 
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not affected by pre-incubation with the motif peptide.  These results suggested that the 
mAbs in the groups I, III and IV recognize epitopes in the motif peptide in the Ig-like 
domain of Fca/mR.  
 Although the mAbs in the groups I, III and IV block the IgA and IgM 
bindings to mFca/mR as a result of competitive binding to the motif peptide which is 
conserved also in human Fca/mR, only the mAbs in group III cross-reacted to human 
Fca/mR (Table 1).  There is one amino acid difference between the motif peptide 
sequences of mouse and human Fca/mR (Fig 3A), which might be involved in epitopes 
recognized by the mAbs in groups I and IV.  It should be noted that, while the motif 
peptide is also highly conserved in mouse, human and rat poly-IgR (Fig 3A), no mAbs 
in the group I to V cross-reacted to the mouse poly-IgR (data not shown).   
 In conclusion, by using mice deficient in Fca/mR gene, we have successfully 
developed anti-mFca/mR mAbs recognizing epitopes within the highly conserved 
peptide in mouse, human and rat Fca/mR.  These mAbs efficiently block the IgA and 
IgM bindings to mFca/mR, suggesting the presence of IgA and IgM binding site in the 
peptide sequence of Fca/mR as well as poly-IgR.  These mAbs should be helpful for 
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molecular and functional characterization of IgA and IgM interaction with Fca/mR.   
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Figure legends 
 
Figure 1.  Competitive binding analyses between anti-mFca/mR mAbs 
BW5147 transfectant expressing mFca/mR was pre-incubated with each mAb and then 
stained with biotinylated mAb indicated, followed with FITC-conjugated streptavidine 
and analyzed by flow cytometry.  Data are shown in relative mean fluorescence 
intensity (MFI) of transfectant stained with biotynyated antibodies after preincubation 
with each mAb, as compared with that stained with biotynyated antibodies alone.  Data 
are representative from more than three independent experiments.  
 
Figure 2.  Competitive binding analyses between anti-mFca/mR mAbs and IgA or 
IgM  
BW5147 transfectant expressing mFca/mR was pre-incubated with each mAb indicated 
(bold lines) or control Ig (dotted lines) and then stained with FITC-conjugated mouse 
IgA or IgM and analyzed by flow cytometry.  Shaded histograms indicate 
autofluorescence of the transfectant. Data are representative from more than three 
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independent experiments.  
 
Figure 3.  Competitive binding analyses between mFca/mR mAbs and a peptide 
from the conserved amino acids sequency 
(A) The conserved amino acid sequences in the Ig-like domain of Fca/mR and in the 
first Ig-like domain of poly-IgR are shown in each species indicated.  The peptide in 
the box was used for the competitive binding analyses for (B). 
(B) Biotin-conjugated anti-mFca/mR mAb indicated was incubated with the peptide 
derived from the conserved amino acid sequences, as shown in box (A), or OVA peptide 
at variable concentrations indicated.  BW5147 transfectant expressing mFca/mR was 
stained with the antibody-peptide mixtures, followed by FITC-conjugated streptavidin 
and analyzed by flow cytometry.  Data are shown in relative MFI of the transfectant 
stained with antibody-motif peptide mixtures, as compared with that stained with 
antibody-control peptide (OVA) mixtures. Data are representative from more than three 
independent experiments.  
 
